Australia grabbed three early wickets, including the prized scalp of star batsman Virat Kohli, to have India on the ropes early on the opening day of the first Test in Adelaide.
Reported by News24 1 hour ago.
Sport24.co.za | Kohli falls as Australia strikes put India on ropes
↧
↧
Asian stocks in retreat once again, Nikkei dropping below ¥21,500
· *Asia sees red as major indexes decline across the board.*
· *Investor confidence is evaporating as quickly as it appeared earlier this week.*
· *Canada arrests Huawei CFO for extradition to the US.*
Pacific-Asia equities are red across the board for Thursday as investor sentiment continues to sour further, and traders are punishing the major indices in the Asian market window, pummeling Japanese and Chinese bourses, while Australia remains surprisingly upright despite a big miss for the Aussie Trade Balance. Canada's arrest of Huawei's global CFO is also expected to see a rise in trade tensions between the US and China, and the move is poorly timed as the two nations were supposed to begin sitting down to a three-month period of trade negotiations.
Japan is steeping in the red for Thursday, with the Nikkei 225 down over -2.5% into 21,360 while Tokyo's Topix index sees declines of -2.25%. China is similarly in retreat, with Hong Kong's Hang Seng index declining -2.60% while Shanghai's CSI 300 see declines near -1.95%.
Emerging markets are also seeing weakness with the MSCI broad Asia-Pacific (excluding Japan) index in the red for -1.10%, but Australia's ASX 200 is down a scant -2.0%, a surprising turnout given the Aussie's $600 million miss on Trade Balance figures early in the day.
Trade war fears and increasing signs of a global economic slowdown have left Pacific-Asia investors risk-averse, and the souring mood surrounding the Trump-Xi tariff truce is doing little to help as traders brace for reheating trade tensions in the near future.
*Nikkei 225 Technical Levels*
Nikkei 225
Overview:
Today Last Price: 21420
Today Daily change: -4.0e+4 pips
Today Daily change %: -1.81%
Today Daily Open: 21815
Trends:
Previous Daily SMA20: 21841.82
Previous Daily SMA50: 22217.63
Previous Daily SMA100: 22580.22
Previous Daily SMA200: 22412.89
Levels:
Previous Daily High: 21980
Previous Daily Low: 21815
Previous Weekly High: 22435
Previous Weekly Low: 21484
Previous Monthly High: 22570
Previous Monthly Low: 21180
Previous Daily Fibonacci 38.2%: 21878.03
Previous Daily Fibonacci 61.8%: 21916.97
Previous Daily Pivot Point S1: 21760
Previous Daily Pivot Point S2: 21705
Previous Daily Pivot Point S3: 21595
Previous Daily Pivot Point R1: 21925
Previous Daily Pivot Point R2: 22035
Previous Daily Pivot Point R3: 22090
Reported by FXstreet.com 1 hour ago.
· *Investor confidence is evaporating as quickly as it appeared earlier this week.*
· *Canada arrests Huawei CFO for extradition to the US.*
Pacific-Asia equities are red across the board for Thursday as investor sentiment continues to sour further, and traders are punishing the major indices in the Asian market window, pummeling Japanese and Chinese bourses, while Australia remains surprisingly upright despite a big miss for the Aussie Trade Balance. Canada's arrest of Huawei's global CFO is also expected to see a rise in trade tensions between the US and China, and the move is poorly timed as the two nations were supposed to begin sitting down to a three-month period of trade negotiations.
Japan is steeping in the red for Thursday, with the Nikkei 225 down over -2.5% into 21,360 while Tokyo's Topix index sees declines of -2.25%. China is similarly in retreat, with Hong Kong's Hang Seng index declining -2.60% while Shanghai's CSI 300 see declines near -1.95%.
Emerging markets are also seeing weakness with the MSCI broad Asia-Pacific (excluding Japan) index in the red for -1.10%, but Australia's ASX 200 is down a scant -2.0%, a surprising turnout given the Aussie's $600 million miss on Trade Balance figures early in the day.
Trade war fears and increasing signs of a global economic slowdown have left Pacific-Asia investors risk-averse, and the souring mood surrounding the Trump-Xi tariff truce is doing little to help as traders brace for reheating trade tensions in the near future.
*Nikkei 225 Technical Levels*
Nikkei 225
Overview:
Today Last Price: 21420
Today Daily change: -4.0e+4 pips
Today Daily change %: -1.81%
Today Daily Open: 21815
Trends:
Previous Daily SMA20: 21841.82
Previous Daily SMA50: 22217.63
Previous Daily SMA100: 22580.22
Previous Daily SMA200: 22412.89
Levels:
Previous Daily High: 21980
Previous Daily Low: 21815
Previous Weekly High: 22435
Previous Weekly Low: 21484
Previous Monthly High: 22570
Previous Monthly Low: 21180
Previous Daily Fibonacci 38.2%: 21878.03
Previous Daily Fibonacci 61.8%: 21916.97
Previous Daily Pivot Point S1: 21760
Previous Daily Pivot Point S2: 21705
Previous Daily Pivot Point S3: 21595
Previous Daily Pivot Point R1: 21925
Previous Daily Pivot Point R2: 22035
Previous Daily Pivot Point R3: 22090
Reported by FXstreet.com 1 hour ago.
↧
Where to now for axed Mitch Marsh?
Allrounder Mitch Marsh has found himself on the margins of Australia's Test and ODI squads a year after scoring his maiden Test century.
Reported by SBS 55 minutes ago.
↧
Honda wants more from Victory youngsters
Melbourne Victory's import pair Keisuke Honda and Georg Niedermeier are loving life in Australia, but bemused at the focus on their training standards.
Reported by Brisbane Times 48 minutes ago.
↧
Aussies on best behaviour in first Test
Australia's cricketers have opted to kill 'em with kindness on day one of a fresh warm and fuzzy era against India.
Reported by SBS 35 minutes ago.
↧
↧
Philip Wilson: Ex-archbishop's conviction for covering-up abuse is quashed
Symbol copyright AFP Symbol caption Philip Wilson were convicted in Might of concealing kid sexual abuse A former Catholic archbishop in Australia has had his conviction for concealing kid sexual abuse quashed. A pass judgement on in New South Wales stated there have been affordable doubts about Philip Wilson’s conviction. Mr Wilson, 68, had turn …
Reported by The News Articles 54 minutes ago.
↧
Killing them with kindness: Aussies on best behaviour in first Test
Australia's cricketers preferred smiles to snarls, and to kill 'em with kindness, on day one of a fresh warm and fuzzy era.
Reported by Brisbane Times 28 minutes ago.
↧
Kuros Reports Publication of MagnetOs Data Demonstrating Equivalence to Autologous Bone in Spinal Fusion
· *Study should further enhance competitive positioning of MagnetOs*
· *Sheep animal model is one of the most relevant preclinical models and believed to be predictive of outcomes in humans*
· *12-week fusion rate with MagnetOs granules & putty 92% & 83% versus autograft 75%*
SCHLIEREN (ZURICH), Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study concluded that MagnetOs is a suitable alternative to autograft when used as a standalone graft.
The publication, which is entitled "Biphasic calcium phosphate with submicron surface topography in an Ovine model of instrumented posterolateral spinal fusion” was included in the December issue JOR Spine, an open-access Orthopaedic Research Society (ORS) journal.
Joost de Bruijn, Chief Executive Officer of Kuros, said: “This latest study demonstrates early bone healing and physiologically-appropriate graft resorption for MagnetOs in this clinically-relevant model of posterolateral spinal fusion and adds to the growing body of evidence proving that MagnetOs is a reliable alternative to autologous bone graft.”
Professor Bill Walsh, University of New South Wales, Australia, who was principal investigator of the study said: “I’ve investigated many of the leading synthetic bone grafts in this model and, in my experience, MagnetOs leads to the most compelling fusion outcomes of all the grafts I’ve tested.”
*About the study*
MagnetOs Granules and MagnetOs Putty were implanted standalone and compared to autograft bone. Twenty-five adult, female Merino sheep underwent posterolateral spinal fusion at L2-3 and L4-5 levels with instrumentation. After 6, 12, and 26 weeks, outcomes were evaluated by manual palpation, range of motion testing, micro-computed tomography, histology and histomorphometry. Fusion assessment by manual palpation 12 weeks after implantation revealed 100% fusion rates in all treatment groups. Similarly, the three treatment groups showed a statistically significant decrease in lateral bending at the fusion levels at 12 weeks and 26 weeks compared to the 6-week time-point, which further confirmed spinal fusion. No significant differences in range of motion were observed between the treatment groups at any of the time-points investigated. Histological assessment at 12 weeks showed fusion rates of 75%, 92%, and 83% for autograft, MagnetOs Granules and MagnetOs Putty, respectively. The fusion rates were further increased 26 weeks post-implantation. Similar trends of bone growth were observed by histomorphometry.
*Citation *
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jsp2.1039
*For further information, please contact: *
Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com
Media & Investors
Hans Herklots
LifeSci Advisors
+41 79 598 7149
hherklots@lifesciadvisors.com*About MagnetOs*
MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is a bone graft comprising biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, resulting in an osteoinductive claim in Europe. MagnetOs is available as granules and as a putty formulation.
*US indications statement*
MagnetOs is an implant intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. MagnetOs must be used with autograft as a bone graft extender in the posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.
*EU indications statement*
MagnetOs is intended for use as bone void filler for voids and gaps that are not intrinsic to the stability of the bony structure. MagnetOs is indicated for use in the treatment of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone. MagnetOs is intended to be packed into bony voids or gaps of the skeletal system (i.e. extremities, spine, cranial, mandible, maxilla and pelvis) and may be combined with autogenous bone. MagnetOs should not be used to treat large defects that in the surgeon’s opinion would fail to heal spontaneously. In load bearing situations, MagnetOs is to be used in conjunction with internal or external fixation devices.
*About Kuros Biosciences AG *
Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.
*Forward Looking Statements *
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. Reported by GlobeNewswire 39 minutes ago.
· *Sheep animal model is one of the most relevant preclinical models and believed to be predictive of outcomes in humans*
· *12-week fusion rate with MagnetOs granules & putty 92% & 83% versus autograft 75%*
SCHLIEREN (ZURICH), Switzerland, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study concluded that MagnetOs is a suitable alternative to autograft when used as a standalone graft.
The publication, which is entitled "Biphasic calcium phosphate with submicron surface topography in an Ovine model of instrumented posterolateral spinal fusion” was included in the December issue JOR Spine, an open-access Orthopaedic Research Society (ORS) journal.
Joost de Bruijn, Chief Executive Officer of Kuros, said: “This latest study demonstrates early bone healing and physiologically-appropriate graft resorption for MagnetOs in this clinically-relevant model of posterolateral spinal fusion and adds to the growing body of evidence proving that MagnetOs is a reliable alternative to autologous bone graft.”
Professor Bill Walsh, University of New South Wales, Australia, who was principal investigator of the study said: “I’ve investigated many of the leading synthetic bone grafts in this model and, in my experience, MagnetOs leads to the most compelling fusion outcomes of all the grafts I’ve tested.”
*About the study*
MagnetOs Granules and MagnetOs Putty were implanted standalone and compared to autograft bone. Twenty-five adult, female Merino sheep underwent posterolateral spinal fusion at L2-3 and L4-5 levels with instrumentation. After 6, 12, and 26 weeks, outcomes were evaluated by manual palpation, range of motion testing, micro-computed tomography, histology and histomorphometry. Fusion assessment by manual palpation 12 weeks after implantation revealed 100% fusion rates in all treatment groups. Similarly, the three treatment groups showed a statistically significant decrease in lateral bending at the fusion levels at 12 weeks and 26 weeks compared to the 6-week time-point, which further confirmed spinal fusion. No significant differences in range of motion were observed between the treatment groups at any of the time-points investigated. Histological assessment at 12 weeks showed fusion rates of 75%, 92%, and 83% for autograft, MagnetOs Granules and MagnetOs Putty, respectively. The fusion rates were further increased 26 weeks post-implantation. Similar trends of bone growth were observed by histomorphometry.
*Citation *
https://onlinelibrary.wiley.com/doi/pdf/10.1002/jsp2.1039
*For further information, please contact: *
Kuros Biosciences AG
Michael Grau
Chief Financial Officer
Tel +41 44 733 47 47
michael.grau@kurosbio.com
Media & Investors
Hans Herklots
LifeSci Advisors
+41 79 598 7149
hherklots@lifesciadvisors.com*About MagnetOs*
MagnetOs promotes local bone formation equivalent to current gold standard, autograft. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is a bone graft comprising biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, resulting in an osteoinductive claim in Europe. MagnetOs is available as granules and as a putty formulation.
*US indications statement*
MagnetOs is an implant intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. MagnetOs must be used with autograft as a bone graft extender in the posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.
*EU indications statement*
MagnetOs is intended for use as bone void filler for voids and gaps that are not intrinsic to the stability of the bony structure. MagnetOs is indicated for use in the treatment of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone. MagnetOs is intended to be packed into bony voids or gaps of the skeletal system (i.e. extremities, spine, cranial, mandible, maxilla and pelvis) and may be combined with autogenous bone. MagnetOs should not be used to treat large defects that in the surgeon’s opinion would fail to heal spontaneously. In load bearing situations, MagnetOs is to be used in conjunction with internal or external fixation devices.
*About Kuros Biosciences AG *
Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.
*Forward Looking Statements *
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. Reported by GlobeNewswire 39 minutes ago.
↧
Nyrstar announces signing of USD650 million committed trade finance framework agreement
Regulated Information - Inside Information
6 December 2018 at 07:00 CET
On 21 November 2018, Nyrstar NV ("Nyrstar" or the "Company", together with its subsidiaries, the "Group") announced that it had signed a binding term sheet with Trafigura Pte Ltd ("Trafigura") under which Trafigura would extend USD650 million of committed liquidity in favour of Nyrstar Sales & Marketing AG ("NSM"). Nyrstar is pleased to announce that this has been documented into a New USD650 million Trade Finance Framework Agreement (the "New USD650m Agreement") which has now been signed.
The USD220 million interim prepayment agreement equally announced on 21 November 2018 will now be replaced and refinanced by the New USD650m Agreement.
The New USD650m Agreement comprises a USD450 million committed revolving prepayment facility (L+5% p.a.) and revolving open account and revolving letter of credit guarantee facilities totalling USD200 million. The agreement matures on 30 June 2020.
The New USD650m Agreement will benefit from a comprehensive guarantee and security package comprising financial guarantees from 12 Group companies that are (together with NSM) currently the guarantors/issuers under the Group's bonds pledges over shares of certain subsidiaries; and pledges over some assets as published on 21 November 2018. It contains customary financial covenants, events of default and other undertakings. The New USD650m Agreement incorporates a right to participate for up to 50% of any future financing or recapitalisation arrangements entered into by the Group, for a period of two years after the date when the new facility becomes effective.
NSM's existing USD250 million working capital facility agreement with Trafigura, which was originally entered into in May 2016 as amended from time to time, will be cancelled and replaced by the New USD650m Agreement.
The New USD650m Agreement significantly strengthens the Group's liquidity position following certain working capital outflows experienced in the period. Nyrstar, together with its advisers, will now continue to focus on the previously announced and ongoing capital structure review.
*About Nyrstar*
Nyrstar is a global multi-metals business, with a market leading position in zinc and lead, and growing positions in other base and precious metals, which are essential resources that are fuelling the rapid urbanisation and industrialisation of our changing world. Nyrstar has mining, smelting and other operations located in Europe, the Americas and Australia and employs approximately 4,100 people. Nyrstar is incorporated in Belgium and has its corporate office in Switzerland. Nyrstar is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: www.nyrstar.com.
*For further information contact:*
Anthony Simms Head of Investor Relations T: +41 44 745 8157 M: +41 79 722 2152 anthony.simms@nyrstar.com
Franziska Morroni Head of Communications T: +41 44 745 8295 M: +41 79 719 2342 franziska.morroni@nyrstar.com
The full press release can be downloaded from the following link:
*Attachment*
· Press Release (English).pdf Reported by GlobeNewswire 39 minutes ago.
6 December 2018 at 07:00 CET
On 21 November 2018, Nyrstar NV ("Nyrstar" or the "Company", together with its subsidiaries, the "Group") announced that it had signed a binding term sheet with Trafigura Pte Ltd ("Trafigura") under which Trafigura would extend USD650 million of committed liquidity in favour of Nyrstar Sales & Marketing AG ("NSM"). Nyrstar is pleased to announce that this has been documented into a New USD650 million Trade Finance Framework Agreement (the "New USD650m Agreement") which has now been signed.
The USD220 million interim prepayment agreement equally announced on 21 November 2018 will now be replaced and refinanced by the New USD650m Agreement.
The New USD650m Agreement comprises a USD450 million committed revolving prepayment facility (L+5% p.a.) and revolving open account and revolving letter of credit guarantee facilities totalling USD200 million. The agreement matures on 30 June 2020.
The New USD650m Agreement will benefit from a comprehensive guarantee and security package comprising financial guarantees from 12 Group companies that are (together with NSM) currently the guarantors/issuers under the Group's bonds pledges over shares of certain subsidiaries; and pledges over some assets as published on 21 November 2018. It contains customary financial covenants, events of default and other undertakings. The New USD650m Agreement incorporates a right to participate for up to 50% of any future financing or recapitalisation arrangements entered into by the Group, for a period of two years after the date when the new facility becomes effective.
NSM's existing USD250 million working capital facility agreement with Trafigura, which was originally entered into in May 2016 as amended from time to time, will be cancelled and replaced by the New USD650m Agreement.
The New USD650m Agreement significantly strengthens the Group's liquidity position following certain working capital outflows experienced in the period. Nyrstar, together with its advisers, will now continue to focus on the previously announced and ongoing capital structure review.
*About Nyrstar*
Nyrstar is a global multi-metals business, with a market leading position in zinc and lead, and growing positions in other base and precious metals, which are essential resources that are fuelling the rapid urbanisation and industrialisation of our changing world. Nyrstar has mining, smelting and other operations located in Europe, the Americas and Australia and employs approximately 4,100 people. Nyrstar is incorporated in Belgium and has its corporate office in Switzerland. Nyrstar is listed on Euronext Brussels under the symbol NYR. For further information please visit the Nyrstar website: www.nyrstar.com.
*For further information contact:*
Anthony Simms Head of Investor Relations T: +41 44 745 8157 M: +41 79 722 2152 anthony.simms@nyrstar.com
Franziska Morroni Head of Communications T: +41 44 745 8295 M: +41 79 719 2342 franziska.morroni@nyrstar.com
The full press release can be downloaded from the following link:
*Attachment*
· Press Release (English).pdf Reported by GlobeNewswire 39 minutes ago.
↧
↧
Forex Today: Risk-off at full steam in Asia, a quiet session ahead
Risk-off sentiment remains the main underlying theme in Asia across the financial markets this Thursday, mainly driven by the renewed tensions between the US and China after the Chinese company, Huawei, Chief Financial Officer (CFO) was arrested by Canada on the US” request and faces extradition to the US. In response to this, China is enraged as the Global Times reported that the US and Canada have no right to detain a Chinese citizen.
As a result, the safe-haven assets got a boost at the expense of the risk-assets took, with the Aussie hit the hardest amid a sharp drop in the Australian trade surplus. The Kiwi followed suit as a sell-off in the Asian equities and oil prices added to the weight on the prices. The Yen, on the other hand, outperformed that pulled the USD/JPY pair back towards the 112.50 level while gold prices on Comex consolidated in multi-week tops below the 1250 upside barrier. Meanwhile, the US dollar traded broadly subdued, pressured by the inversion of the Treasury yields.
*Main Topics in Asia*
Australian Trade Balance misses, declines sharply to $2.316 billion on Imports upswing
CBI: UK facing exetreme risks in disorderly Brexit - Reuters
BoJ’s Kuroda: BoJ must communicate its exit strategy but only when it hits the price target
BoJ's Kuroda: No specific upper limit for bond purchases
Brent oil Technical Analysis: This MA line is capping the recovery rally ahead of OPEC meeting
Fed’s Quarles: Comfortable that level of financial risk is ‘moderate’
Moody’s: The outlook for Australia’s infrastructure sector is stable next year
Gold consolidates near 5.5-week highs amid US yield curve inversion
Adviser: PBOC to allow Yuan to gain in trade truce - MNI
Iran’s OilMin Zanganeh: Iran looking for exemption from any oil output cuts
*Key Focus Ahead*
We have a data-quiet European calendar, with the only German factory orders dropping in at 0700 GMT. Hence, the focus remains on the Brexit developments, as the debate for the Parliamentary vote on the Brexit deal gets started later on today. Also, the outcome of the much-awaited OPEC meeting due to be announced at 1200 GMT will have a major impact on the oil markets and eventually on the broader market sentiment, as US-China trade woes continue to undermine.
In contrast, the NA session remains quite eventful, with a host of economic releases due on the cards from the US docket, including the ADP jobs report at 1315 GMT that will be followed by the weekly jobless claims and trade data at 1330 GMT. At the same time, the Canadian trade figures will be out just ahead of the speech by BOC Governor Poloz at 1350 GMT. Later on 1500 GMT, the US ISM services PMI will be reported alongside the factory orders data and Canadian Ivey PMI. Thereafter, the oil markets will watch out for the EIA crude stocks data at 1530 GMT.
*Besides, the following central bankers speeches will also remain in focus for further trading impetus.*
0905 GMT: RBA Assistant Governor Debelle
1350 GMT: BOC Governor Poloz
Around 1500 GMT: Fed Chair Powell
1715 GMT: FOMC member Bostic
EUR/USD: Focus on yield differentials
Italy-German 10-year yield spread has narrowed to 279 basis points - the lowest level since Oct. 4. So far, however, that has not put a bid under the EUR, possibly due to fears of economic recession stemming from the Treasury yield curve inversion.
GBP/USD floundering near 1.2700 as the Brexit clock continues to tick down
Thursday remains clear of any GBP-related data, and the GBP/USD pairing remains trapped in tense markets ahead of the December 11th Brexit cut-off.
GBP to fall nearly 3% if parliament rejects Brexit deal – Reuters poll
According to the results of the latest Reuters poll of economists, a majority of them believe that the British currency, the *GBP*, is poised for a 2.75% fall should the parliament reject the Brexit deal.
OPEC Dec 6th Vienna meeting preview: Agenda and timings
The much-awaited meeting of the Organisation of Petroleum Exporting Countries (OPEC) is due on the cards later today that will have a significant impact on the oil price-action in the coming months.
ADP employment preview: job creation expected to remain healthy
American employers are thought to have maintained their strong recruitment in November with 195,000 new positions on the books at the payroll processing giant ADP.
Reported by FXstreet.com 35 minutes ago.
As a result, the safe-haven assets got a boost at the expense of the risk-assets took, with the Aussie hit the hardest amid a sharp drop in the Australian trade surplus. The Kiwi followed suit as a sell-off in the Asian equities and oil prices added to the weight on the prices. The Yen, on the other hand, outperformed that pulled the USD/JPY pair back towards the 112.50 level while gold prices on Comex consolidated in multi-week tops below the 1250 upside barrier. Meanwhile, the US dollar traded broadly subdued, pressured by the inversion of the Treasury yields.
*Main Topics in Asia*
Australian Trade Balance misses, declines sharply to $2.316 billion on Imports upswing
CBI: UK facing exetreme risks in disorderly Brexit - Reuters
BoJ’s Kuroda: BoJ must communicate its exit strategy but only when it hits the price target
BoJ's Kuroda: No specific upper limit for bond purchases
Brent oil Technical Analysis: This MA line is capping the recovery rally ahead of OPEC meeting
Fed’s Quarles: Comfortable that level of financial risk is ‘moderate’
Moody’s: The outlook for Australia’s infrastructure sector is stable next year
Gold consolidates near 5.5-week highs amid US yield curve inversion
Adviser: PBOC to allow Yuan to gain in trade truce - MNI
Iran’s OilMin Zanganeh: Iran looking for exemption from any oil output cuts
*Key Focus Ahead*
We have a data-quiet European calendar, with the only German factory orders dropping in at 0700 GMT. Hence, the focus remains on the Brexit developments, as the debate for the Parliamentary vote on the Brexit deal gets started later on today. Also, the outcome of the much-awaited OPEC meeting due to be announced at 1200 GMT will have a major impact on the oil markets and eventually on the broader market sentiment, as US-China trade woes continue to undermine.
In contrast, the NA session remains quite eventful, with a host of economic releases due on the cards from the US docket, including the ADP jobs report at 1315 GMT that will be followed by the weekly jobless claims and trade data at 1330 GMT. At the same time, the Canadian trade figures will be out just ahead of the speech by BOC Governor Poloz at 1350 GMT. Later on 1500 GMT, the US ISM services PMI will be reported alongside the factory orders data and Canadian Ivey PMI. Thereafter, the oil markets will watch out for the EIA crude stocks data at 1530 GMT.
*Besides, the following central bankers speeches will also remain in focus for further trading impetus.*
0905 GMT: RBA Assistant Governor Debelle
1350 GMT: BOC Governor Poloz
Around 1500 GMT: Fed Chair Powell
1715 GMT: FOMC member Bostic
EUR/USD: Focus on yield differentials
Italy-German 10-year yield spread has narrowed to 279 basis points - the lowest level since Oct. 4. So far, however, that has not put a bid under the EUR, possibly due to fears of economic recession stemming from the Treasury yield curve inversion.
GBP/USD floundering near 1.2700 as the Brexit clock continues to tick down
Thursday remains clear of any GBP-related data, and the GBP/USD pairing remains trapped in tense markets ahead of the December 11th Brexit cut-off.
GBP to fall nearly 3% if parliament rejects Brexit deal – Reuters poll
According to the results of the latest Reuters poll of economists, a majority of them believe that the British currency, the *GBP*, is poised for a 2.75% fall should the parliament reject the Brexit deal.
OPEC Dec 6th Vienna meeting preview: Agenda and timings
The much-awaited meeting of the Organisation of Petroleum Exporting Countries (OPEC) is due on the cards later today that will have a significant impact on the oil price-action in the coming months.
ADP employment preview: job creation expected to remain healthy
American employers are thought to have maintained their strong recruitment in November with 195,000 new positions on the books at the payroll processing giant ADP.
Reported by FXstreet.com 35 minutes ago.
↧
Asian shares skid as Huawei CFO arrest revives trade jitters
TOKYO (AP) — Asian stock prices skidded Thursday following the arrest of a senior official at Chinese telecoms equipment maker Huawei that could derail progress in China-U.S. trade talks. KEEPING SCORE: Hong Kong's Hang Seng index tumbled 2.7 percent to 26,081.73 and Japan's benchmark Nikkei 225 fell 2.5 percent to 21,373.83. Australia's S&P/ASX 200 lost 0.2 percent to 5,657.60, while South Korea's Kospi sank 1.6 percent to 2,068.56. The Shanghai Composite index dropped 1.7 percent to 2,6043.91. Shares also fell in Taiwan and all other regional markets. WALL STREET: Markets were closed in the U.S. on Wednesday for a day of mourning following the death of former U.S. President George H.W. Bush.
Reported by SeattlePI.com 35 minutes ago.
↧
Core Lithium eyes higher valuation potential for Finniss Lithium Project
Core Lithium Ltd (ASX:CXO) has intersected substantial new spodumene mineralised pegmatites from recent drilling at its Finniss Lithium Project in the Northern Territory. The company is awaiting drill assays from this exploration/resource drilling and will aim to complete the resource assessment process for each of Carlton, Hang Gong and Lees-Booths Link. Core is expected to reveal substantially expanded resources for the project over the next two months. READ: Core Lithium releases maiden lithium resource for Sandras, shares rise Given the expected material change in the resource, Core has formed the view that the definitive feasibility study (DFS) process needs to recognise this in order to deliver an optimal outcome in terms of the size and scheduling of the mining operations. Core managing director Stephen Biggins said: “It was a difficult decision to defer the release of the DFS, however the positive exploration results and expected substantial mineral resource increase meant that we would have released a study that would have dated very quickly, and would not reflect the project we believe Core will ultimately develop. READ: Core Lithium reveals high-grade lithium hits at Finniss project ahead of resource update “In the context of the recently announced $1.58 billion deal to sell half the Wodgina Lithium Project from Mineral Resources (ASX:MIN) to Albemarle, Core is understandably keen to maximise the resources and valuation potential of the Finniss Lithium Project. “Given we are not expecting regulatory and other approvals before the start of Q2 2019, we believe it makes much more sense to incorporate the new information and ensure that we have the best project possible before we commit shareholder’s funds to development. “We look forward to the release of the mineral resource upgrades over the coming weeks and our plans to be Australia’s next lithium producer.” Capital raising Core’s binding offtake partner Yahua and non-binding offtake partner Ruifu, being two of China’s largest lithium producers, have committed to $1.5 million of new equity at 5 cents per share to accelerate resource drilling programs of the recently discovered prospects and delivery of the expanded scope of the DFS. Both Ruifu and Core continue to work diligently towards execution of binding agreements, with the expectation of completion in Q1 2019. In addition to the $1.5 million strategic placement, Core is finalising plans for the balance of additional new equity up to a further $2.5 million to be raised on the same terms.
Reported by Proactive Investors 18 minutes ago.
↧
Magnitude 6 Quake Strikes Off Australia's Norfolk Island – USGS
Reported by RIA Nov. 11 minutes ago.
↧
↧
Quake of magnitude 6 strikes northeast of Australia's Norfolk Island: USGS
A shallow earthquake of magnitude 6 struck northeast of Australia's Norfolk Island on Thursday, the United States Geological Survey said.
Reported by Reuters 5 minutes ago.
↧
MRI Systems Market to Reach $7.9 billion by 2023: P&S Intelligence
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- *MRI Systems Market by Architecture (Closed, Open), by Type (Fixed, Mobile), by Field Strength (High Field, Very High Field, Low to Mid Field, Ultra-High Field, by Application (Brain, Head, & Neck, Spine, Musculoskeletal, Vascular, Pelvic & Abdomen, Breast, Cardiac), by End User (Hospitals & Clinics, Diagnostic Centers), by Geography (U.S., Canada, Germany, France, U.K., Italy, Spain, Japan, China, India, Brazil, Mexico) – Global Market Size, Share, Development, Growth and Demand Forecast, 2013–2023*According to the market research report published by P&S Intelligence, MRI systems market is expected to reach $7.9 billion by 2023. Rising prevalence of chronic diseases, surging geriatric population, growing awareness on the early diagnosis of diseases, and technological advancements are the key factors boosting the market growth, globally.
*Request to get the sample pages of the report: *https://www.psmarketresearch.com/market-analysis/mri-market/report-sample
On the basis of architecture, the MRI systems market has been categorized into closed and open MRI. Of the two, open imaging systems are expected to witness faster market growth during the forecast period. The market for these systems is projected to reach $1,730.0 million by 2023, registering a CAGR of 6.5% during the forecast period. Since the elderly are often uncomfortable with the idea of undergoing long-duration MRI scanning in closed MRI settings, the demand for open imaging systems is expected to be high during the forecast period.
The MRI systems market has also been categorized into high-field, very-high-field, low-to-mid-field, and ultra-high-field imaging systems. High-field systems generated the highest revenue in the MRI systems market during the historical period, with a contribution of $3,031.7 million in 2017. This can be mainly ascribed to the fact that a high-field imaging system has faster imaging capability as comparison to low-field-strength systems and is primarily used for the scanning of the abdomen and the chest.
MRI systems are used for the imaging of the brain, head, and neck; spine; pelvis and abdomen; breast; musculoskeletal; vascular; cardiac; and other areas. Brain, head, and neck imaging is the largest application area of these systems, in terms of both market size and growth. MRI systems are largely used for the scanning of the brain, head, and neck, owing to the increasing number of brain injury cases reported globally.
*Browse report overview with 215 tables and 61 figures spread through 234 pages and detailed TOC on* *"MRI Systems Market” at: *https://www.psmarketresearch.com/market-analysis/mri-market
During the forecast period, the MRI systems market is expected to witness the fastest growth in the APAC region, with 6.0% CAGR. The market in the region is primarily driven by improving healthcare infrastructure, increasing prevalence of chronic diseases, and technological advancements in imaging modalities. According to Cancer Australia, a cancer control agency by the Australian Government, 127,887 new cases of cancer were diagnosed in Australia in 2014, and the number is expected to reach 138,321 by the end of 2018.
Companies operating in the MRI systems industry are collaborating with healthcare firms and academic institutes to offer innovative products. For instance, in March 2018, Koninklijke Philips N.V. (Philips) and Hologic Inc. entered into an agreement to provide a complete set of innovative diagnostic imaging systems, software, and services for women healthcare. Under the agreement, both the companies will select products from each other’s portfolios as a part of multi-modality deals for hospitals and health systems.
*Make enquiry before buying the report: *https://www.psmarketresearch.com/send-enquiry?enquiry-url=mri-market
Besides, in March 2018, Canon Medical Systems Corporation entered into a collaborative agreement with Kumamoto University and the University of Bordeaux to conduct research on the application of deep learning reconstruction (DLR), an artificial intelligence (AI) based technology in MRI. DLR is a reconstruction technology that helps eliminate noise from images.
Some of the other key players operating in the global MRI systems market are Siemens AG, General Electric Company, Esaote S.p.A., Hitachi Ltd., Fonar Corporation, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Neusoft Medical Systems Co. Ltd., AURORA HEALTHCARE US CORP, Bruker Corporation, Time Medical Holdings, and Aspect Imaging Ltd.
*More Reports by P&S Intelligence*
*MRI Compatible Patient Monitoring Systems Market*
The global MRI compatible patient monitoring systems market is growing, due to increasing installation of MRI devices. The increase in geriatric population worldwide is resulting in the growth of the global MRI compatible patient monitoring systems market, as the geriatric population is more susceptible to diseases, sickness and syndromes, due to less regenerative abilities.
https://www.psmarketresearch.com/market-analysis/magnetic-resonance-imaging-compatible-patient-monitoring-system-market
*Medical Bionics Market*
Global medical bionics market is forecasted to generate a revenue of $28.1 billion by 2023. The market is mainly driven by increasing pool of geriatric population and associated organ failures, rising number of accidents and injuries leading to amputations, and increasing number of people opting for organ transplants.
https://www.psmarketresearch.com/market-analysis/medical-bionics-market
*About P&S Intelligence*
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
*Contact: *
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
*Connect with us: *LinkedIn* | *Twitter* | *Google +* | *Facebook Reported by GlobeNewswire 10 minutes ago.
*Request to get the sample pages of the report: *https://www.psmarketresearch.com/market-analysis/mri-market/report-sample
On the basis of architecture, the MRI systems market has been categorized into closed and open MRI. Of the two, open imaging systems are expected to witness faster market growth during the forecast period. The market for these systems is projected to reach $1,730.0 million by 2023, registering a CAGR of 6.5% during the forecast period. Since the elderly are often uncomfortable with the idea of undergoing long-duration MRI scanning in closed MRI settings, the demand for open imaging systems is expected to be high during the forecast period.
The MRI systems market has also been categorized into high-field, very-high-field, low-to-mid-field, and ultra-high-field imaging systems. High-field systems generated the highest revenue in the MRI systems market during the historical period, with a contribution of $3,031.7 million in 2017. This can be mainly ascribed to the fact that a high-field imaging system has faster imaging capability as comparison to low-field-strength systems and is primarily used for the scanning of the abdomen and the chest.
MRI systems are used for the imaging of the brain, head, and neck; spine; pelvis and abdomen; breast; musculoskeletal; vascular; cardiac; and other areas. Brain, head, and neck imaging is the largest application area of these systems, in terms of both market size and growth. MRI systems are largely used for the scanning of the brain, head, and neck, owing to the increasing number of brain injury cases reported globally.
*Browse report overview with 215 tables and 61 figures spread through 234 pages and detailed TOC on* *"MRI Systems Market” at: *https://www.psmarketresearch.com/market-analysis/mri-market
During the forecast period, the MRI systems market is expected to witness the fastest growth in the APAC region, with 6.0% CAGR. The market in the region is primarily driven by improving healthcare infrastructure, increasing prevalence of chronic diseases, and technological advancements in imaging modalities. According to Cancer Australia, a cancer control agency by the Australian Government, 127,887 new cases of cancer were diagnosed in Australia in 2014, and the number is expected to reach 138,321 by the end of 2018.
Companies operating in the MRI systems industry are collaborating with healthcare firms and academic institutes to offer innovative products. For instance, in March 2018, Koninklijke Philips N.V. (Philips) and Hologic Inc. entered into an agreement to provide a complete set of innovative diagnostic imaging systems, software, and services for women healthcare. Under the agreement, both the companies will select products from each other’s portfolios as a part of multi-modality deals for hospitals and health systems.
*Make enquiry before buying the report: *https://www.psmarketresearch.com/send-enquiry?enquiry-url=mri-market
Besides, in March 2018, Canon Medical Systems Corporation entered into a collaborative agreement with Kumamoto University and the University of Bordeaux to conduct research on the application of deep learning reconstruction (DLR), an artificial intelligence (AI) based technology in MRI. DLR is a reconstruction technology that helps eliminate noise from images.
Some of the other key players operating in the global MRI systems market are Siemens AG, General Electric Company, Esaote S.p.A., Hitachi Ltd., Fonar Corporation, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Neusoft Medical Systems Co. Ltd., AURORA HEALTHCARE US CORP, Bruker Corporation, Time Medical Holdings, and Aspect Imaging Ltd.
*More Reports by P&S Intelligence*
*MRI Compatible Patient Monitoring Systems Market*
The global MRI compatible patient monitoring systems market is growing, due to increasing installation of MRI devices. The increase in geriatric population worldwide is resulting in the growth of the global MRI compatible patient monitoring systems market, as the geriatric population is more susceptible to diseases, sickness and syndromes, due to less regenerative abilities.
https://www.psmarketresearch.com/market-analysis/magnetic-resonance-imaging-compatible-patient-monitoring-system-market
*Medical Bionics Market*
Global medical bionics market is forecasted to generate a revenue of $28.1 billion by 2023. The market is mainly driven by increasing pool of geriatric population and associated organ failures, rising number of accidents and injuries leading to amputations, and increasing number of people opting for organ transplants.
https://www.psmarketresearch.com/market-analysis/medical-bionics-market
*About P&S Intelligence*
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
*Contact: *
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
*Connect with us: *LinkedIn* | *Twitter* | *Google +* | *Facebook Reported by GlobeNewswire 10 minutes ago.
↧
Australia: Retail sales edge ahead - Westpac
Matthew Hassan, Research Analyst at Westpac, points out that Australian retailers reported a 0.3% lift in sales in October, in line with market expectations but better than Westpac's forecast of a 0.1% gain.
*Key Quotes*
“While sales growth is still not strong its looking a touch better than it did mid year, annual growth having lifted from 2.9% in June to 3.6% currently.”
“The detail shows a more uneven story. By store type, the October month saw a strong rise for clothing (2.6%mth) and a solid 0.6% gain for household goods but mixed results for 'small ticket' discretionary store types – 'other retail' up 0.5% but cafes and restaurants down 0.9%. Basic food posted a 0.2% rise.”
“Overall, the October retail sales gain is of some relief given yesterday's disappointing September quarter update on wider consumer spending. That said, the softer tone around some 'discretionary' categories and the slowing in NSW add a clear note of caution. Risks still look skewed to the downside as we head into the all important Christmas period.”
Reported by FXstreet.com 7 minutes ago.
*Key Quotes*
“While sales growth is still not strong its looking a touch better than it did mid year, annual growth having lifted from 2.9% in June to 3.6% currently.”
“The detail shows a more uneven story. By store type, the October month saw a strong rise for clothing (2.6%mth) and a solid 0.6% gain for household goods but mixed results for 'small ticket' discretionary store types – 'other retail' up 0.5% but cafes and restaurants down 0.9%. Basic food posted a 0.2% rise.”
“Overall, the October retail sales gain is of some relief given yesterday's disappointing September quarter update on wider consumer spending. That said, the softer tone around some 'discretionary' categories and the slowing in NSW add a clear note of caution. Risks still look skewed to the downside as we head into the all important Christmas period.”
Reported by FXstreet.com 7 minutes ago.
↧
Australia data encryption laws are a world first
Tech firms say the controversial laws could weaken overall security for users of messenger apps.
Reported by BBC News 2 hours ago.
↧
↧
Sport24.co.za | Australia urges India to get behind day-night Tests
Australia's cricket chief has urged India to reconsider its opposition to day-night Tests with crowd numbers hurt by their refusal to play under lights in Adelaide.
Reported by News24 2 hours ago.
↧
How a tiny box attached to a cow's ear is making waves in space
On the side of a corrugated iron water tank, in the middle of the sun-scorched outback, sits a tiny box the size of a pack of gum. It might be the future of Australia's space ambitions.
Reported by Brisbane Times 2 hours ago.
↧
Relentless Ashwin keeps Australia on a leash
The offie bowled through the second session on Day 2 and now has figures of 3 for 38
Reported by CricBuzz 2 hours ago.
↧
More Pages to Explore .....
